Tuberculosis (TB) Diagnostics Market Size [2022-2028] value

0

PUNE, India, March 01, 2022 (GLOBE NEWSWIRE) — The global Tuberculosis (TB) Diagnostics Market Size was estimated at $1.96 billion in 2020. The market valuation is expected to increase from $2.05 billion in 2021 to $2.87 billion in 2028 at a CAGR of 4.9% over the forecast period. The market is driven by the need for improved diagnostic solutions to address the increasing burden of tuberculosis. Continued advances in TB diagnostics will transform the market outlook in the coming years, according to Fortune Business Insights in its report titled Tuberculosis (TB) Diagnostics Market, 2022-2028.

Tuberculosis (TB) is a highly contagious lung disease caused by Mycobacterium tuberculosis – a type of bacteria that typically attacks the patient’s lungs. The infection can also affect other parts of the body, such as the brain and spine. TB blood test and TB skin test are commonly used methods to detect these bacteria in the body. A significant incidence of the disease worldwide has created the need for improved diagnostic technologies. Active investments in healthcare to manage the increasing burden of the disease will drive the market size in 2022-2028.

Get a PDF sample brochure: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/tuberculosis-tb-diagnostics-market-102009

Report scope and segmentation

report coverage details
forecast period 2021 to 2028
Forecast period 2021 to 2028 CAGR 4.9%
Value prognosis 2028 $2.87 billion
base year 2020
Market size in 2020 $1.96 billion
Historical data for 2017 to 2019
number of pages 127
segments covered Types, end users and geography
growth accelerator Growing public-private partnerships to improve diagnostic capabilities
Increasing prevalence to increase demand for tuberculosis diagnostics
High diagnostic costs to limit adoption

The market will gain traction due to rising TB burden

The main driver for the growth of the tuberculosis (TB) diagnostics market remains the increasing prevalence of tuberculosis worldwide. In 2019, the 30 countries with a high TB ​​burden accounted for more than 87% of all cases worldwide. To counteract the increasing incidence of the disease, a number of technological improvements have been made. One such technology is the molecular assay. For example, the WHO Global Tuberculosis Program included TrueNet, an Indian molecular test that can detect TB and identify residues of the TB bacteria in about 90 minutes. The introduction of such technologies with improved speed, accuracy and reliability will drive the market.

However, market development could be hampered by the high cost of certain diagnostic procedures.

To learn more about the short- and long-term impact of COVID-19 on this market,

Please visit: https://www.fortunebusinessinsights.com/tuberculosis-tb-diagnostics-market-102009

Notable industry developments:

July 2020 – Cepheid, a Danaher subsidiary, launched the Xpert MTB/XDR test in collaboration with the Foundation for Innovative New Diagnostics (FIND). The test can extend drug resistance profiling in TB in less than 90 minutes.

Market segments:

By type, the market is segmented into sputum swab microscopy, culture-based diagnostics, rapid molecular diagnostics, and others.

In terms of end users, the market is divided into hospitals and diagnostic laboratories.

Geographically, the market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

Quick Buy – Tuberculosis (TB) Diagnostics market Research paper: https://www.fortunebusinessinsights.com/checkout-page/102009

Decline in TB testing impacted market growth during the pandemic

Tuberculosis (TB) diagnostics market growth slowed slightly during the COVID-19 pandemic. A significant drop in TB testing has been observed in many regions. The Global Fund survey, released in March 2021, found that in 13 countries with the highest TB burden, around 29% fewer people were tested for TB in 2019. This is because the resources and equipment used to diagnose the disease have been diverted to help fight the COVID-19 pandemic.

Regional Insights:

North America achieved US$0.56 billion market share of the global tuberculosis (TB) diagnostics market in 2020 and will grow significantly through 2028. The regional growth is due to the economically stable and highly conscious population. An established healthcare system and widespread adoption of technologically advanced products will benefit regional prospects.

Europe is expected to experience notable market growth, led by increasing research and development in the field of tuberculosis diagnostics. Meanwhile, the Asia-Pacific market will gain momentum, led by the widespread incidence of TB and a large geriatric population base.

Talk to our analyst: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/tuberculosis-tb-diagnostics-market-102009

The report lists the major players profiled in the market report:

  • F. Hoffmann-La Roche AG (Basel, Switzerland)
  • bioMérieux SA (Marcy l’Etoile, France)
  • QIAGEN (Venlo, Netherlands)
  • BD (Becton, Dickinson and Company) (New Jersey, USA)
  • Danaher (Washington DC, USA)
  • Thermo Fisher Scientific Inc. (Waltham, USA)
  • Abbott (Illinois, USA)
  • Hologic Inc. (Marlborough, USA)
  • Hain Lifescience GmbH (Nehren, Germany)
  • Oxford Immunotec (Abingdon, UK)

Detailed table of contents:

  • introduction
    • research area
    • market segmentation
    • research methodology
    • Definitions and Assumptions
  • Summary
  • market dynamics
    • market leader
    • Market Restrictions
    • market opportunities
  • Important Findings
    • Key Industry Developments
    • Incidence of tuberculosis by key countries
    • Impact of Covid-19 on the market
  • Global Tuberculosis (TB) Diagnostics Market Analysis, Insights and Forecast, 2017-2028
    • Key Findings / Summary
    • Market Analysis, Insights and Forecasts – by Type
      • Culture-based diagnostics
      • Sputum smear microscopy
      • Rapid molecular diagnostics
      • Other
    • Market analysis, insights and forecasts – by end user
      • diagnostic laboratories
      • hospitals
    • Market analysis, insights and forecasts – by region
      • North America
      • Europe
      • Asia Pacific
      • Latin America
      • Middle East & Africa
  • Tuberculosis (TB) Diagnostics Market Analysis, Insights and Forecasts in North America, 2017-2028
    • Key Findings / Summary
    • Market Analysis, Insights and Forecasts – by Type
      • Culture-based diagnostics
      • Sputum smear microscopy
      • Rapid molecular diagnostics
      • Other
    • Market analysis, insights and forecasts – by end user
      • diagnostic laboratories
      • hospitals
    • Market analysis, insights and forecasts – by country
  • Tuberculosis (TB) Diagnostics Market Analysis, Insights and Forecasts in Europe, 2017-2028
    • Key Findings / Summary
    • Market Analysis, Insights and Forecasts – by Type
      • Culture-based diagnostics
      • Sputum smear microscopy
      • Rapid molecular diagnostics
      • Other

Table of contents continued..

Ask to customize this report: https://www.fortunebusinessinsights.com/enquiry/customization/tuberculosis-tb-diagnostics-market-102009

About us:

Fortune Business Insights™ provides expert business analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our customers and support them in overcoming challenges that are specific to their company. Our goal is to provide our clients with holistic market intelligence and a detailed overview of the market in which they operate.

Contact us:

Fortune Business Insights™ Pvt. GmbH.

US: +1 424 253 0390

United Kingdom: +44 2071 939123

APAC: +91 744 740 1245

E-mail: [email protected]

Share.

Comments are closed.